Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wong Janice, Wang Tina, Datta Ritobrato, Abdollahi Rouhollah O, Li Jingwei, Rowe Christopher C, Henley David, Kolb Hartmuth C, Saad Ziad S, Alzheimer's Disease Neuroimaging Initiative
Аннотация
INTRODUCTION: Inhibition of pathological tau spread may slow cognitive decline in Alzheimer's disease. Here, we evaluate two tau positron emission tomography (PET) analysis methods designed for detecting tau spread.
METHODS: Spatial progression of tauopathy (SPOT) and tau-naïve anatomical region of interest (tau-naïve ROI) methods were assessed in two large observational cohorts in amyloid-positive (A+) cognitively unimpaired (CU) or mildly cognitively impaired (MCI) participants versus CU amyloid-negative (A-) participants.
RESULTS: SPOT and tau-naïve ROI demonstrated measurable annualized change in CU A+ and MCI A+ participants versus CU A- participants. These spread estimates produced effect sizes comparable to standardized uptake value ratio (SUVR) change measures in anatomically defined ROIs. Effect sizes were increased when evaluating the subset of tau positive CU A+ and MCI A+ participants.
DISCUSSION: SPOT and tau-naïve ROI methods are designed to measure tau spread and may be used in addition to traditional SUVR measures to evaluate tau progression in AD.
METHODS: Spatial progression of tauopathy (SPOT) and tau-naïve anatomical region of interest (tau-naïve ROI) methods were assessed in two large observational cohorts in amyloid-positive (A+) cognitively unimpaired (CU) or mildly cognitively impaired (MCI) participants versus CU amyloid-negative (A-) participants.
RESULTS: SPOT and tau-naïve ROI demonstrated measurable annualized change in CU A+ and MCI A+ participants versus CU A- participants. These spread estimates produced effect sizes comparable to standardized uptake value ratio (SUVR) change measures in anatomically defined ROIs. Effect sizes were increased when evaluating the subset of tau positive CU A+ and MCI A+ participants.
DISCUSSION: SPOT and tau-naïve ROI methods are designed to measure tau spread and may be used in addition to traditional SUVR measures to evaluate tau progression in AD.